Please ensure Javascript is enabled for purposes of website accessibility

Foolish Forecast: Monsanto 2.0

By Brian Orelli, PhD – Updated Apr 6, 2017 at 11:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Views you can use to get clues on tomorrow's news.

With Monsanto's (NYSE: MON) herbicide Roundup facing cheap generic competition, the agriculture giant has planted its hopes for growth solely in the field of biotech seeds. We'll see how the shift is going on the other side of tomorrow's sunrise, when Monsanto reports results from its fiscal third quarter. Until then, here's a look at what to expect.

What analysts say:

  • Buy, sell, or waffle? Analysts are cautiously optimistic, with seven buys and 10 holds. Two analysts think it's time to sow your cash somewhere else, and have rated Monsanto a sell.
  • Revenue: Top-line growth may be in the green, but just barely. The average analyst's estimate is just $10 million higher than the year-ago quarter -- a rounding error for a company this big.
  • Earnings: With Roundup margins contracting, analysts see the bottom line getting plowed down this quarter, at just $0.80 per share compared to $1.25 per share this time last year.

What management says:
If you can't beat 'em, join 'em. That was management's basic message as it cut its price for Roundup last month. With some competitors using generic Roundup as a loss leader to sell other chemicals, Monsanto couldn't get enough farmers to buy the brand name at premium prices.

Management is hoping investors will stick with the company, even though it estimates the move will create a $0.50-to-$0.70-per-share hit to earnings this fiscal year. Its seed trait business, which competes with the likes of DuPont (NYSE: DD), Dow Chemical (NYSE: DOW), and Syngenta (NYSE: SYT), is still intact and should provide mid-teens earnings growth in 2011 and beyond.

… As long as there aren't any other pricing adjustments, of course.

What management does:
When the cash cow leaves the barn, there's bound to be a hit on margins, as Monsanto has seen over the past few quarters:

Margins

Nov 2008

Feb 2009

May 2009

Aug 2009

Nov 2009

Feb 2010

Gross

55.9%

57.0%

57.7%

58.1%

55.7%

53.0%

Operating

27.2%

28.7%

29.0%

31.3%

26.9%

23.8%

Net

19.4%

18.6%

18.2%

18.0%

14.2%

12.5%

FCF/Revenue

7.4%

11.1%

7.3%

11.3%

(1.3%)

1.8%

All data courtesy of Capital IQ, a division of Standard & Poor's. Data reflects trailing-12-month performance for the quarters ended in the named months.

Management has cut costs where it could; selling, general, and administrative expenses were down 6% year over year in the first half of the fiscal year. But the company has been steadfast in keeping research and development spending intact, even increasing it by about 5% so far this fiscal year.

One Fool says:
If you're going to invest in agriculture, whether in companies that produce seeds and chemicals, like Monsanto, or fertilizers, like Agrium (NYSE: AGU), Mosaic (NYSE: MOS), and PotashCorp (NYSE: POT), you have to be prepared for the cyclical nature of the beast. When the price of crops falls, margins will suffer, as suppliers are forced to lower their prices.

But for Monsanto in particular, you also have to be willing to ride the cyclical nature of patent expirations. Just like pharmaceutical companies facing patent cliffs for their brand-name drugs, Monsanto's loss of a major product will wreak havoc on its earnings.

Fortunately, the year-over-year comparisons will be over soon enough. As long as Monsanto can continue to innovate -- and the fact that it's keeping R&D spending up is a good sign -- the cycle will be on an upswing soon enough.

Motley Fool Rule Breakers is always on the hunt for cutting-edge picks. See all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Syngenta is a Motley Fool Global Gains pick. The Fool's disclosure policy is considered a cash crop in six states.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Monsanto Company Stock Quote
Monsanto Company
MON
Nutrien Stock Quote
Nutrien
POT
E. I. du Pont de Nemours and Company Stock Quote
E. I. du Pont de Nemours and Company
DD
DuPont de Nemours, Inc. Stock Quote
DuPont de Nemours, Inc.
DOW
The Mosaic Company Stock Quote
The Mosaic Company
MOS
$48.53 (-7.60%) $-3.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.